Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was upgraded by stock analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report released on Thursday.
A number of other equities analysts have also weighed in on PAHC. JPMorgan Chase & Co. started coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They set a "neutral" rating and a $22.00 price target on the stock. Bank of America boosted their target price on Phibro Animal Health from $13.00 to $15.00 and gave the stock an "underperform" rating in a report on Friday, August 30th. Finally, Barclays upped their price target on Phibro Animal Health from $13.00 to $20.00 and gave the company an "underweight" rating in a research report on Tuesday, November 12th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $16.50.
Check Out Our Latest Report on Phibro Animal Health
Phibro Animal Health Price Performance
Shares of NASDAQ PAHC traded down $0.02 during midday trading on Thursday, hitting $23.59. The stock had a trading volume of 99,234 shares, compared to its average volume of 158,638. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81. The stock has a 50 day simple moving average of $23.27 and a 200-day simple moving average of $20.14. The company has a market capitalization of $955.40 million, a PE ratio of 54.86, a P/E/G ratio of 0.62 and a beta of 0.51. Phibro Animal Health has a 1 year low of $9.49 and a 1 year high of $25.98.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.07. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. The company had revenue of $273.16 million for the quarter, compared to analyst estimates of $262.44 million. On average, sell-side analysts expect that Phibro Animal Health will post 1.61 EPS for the current fiscal year.
Insider Activity
In other Phibro Animal Health news, Director E Thomas Corcoran bought 5,000 shares of Phibro Animal Health stock in a transaction on Wednesday, September 4th. The shares were bought at an average price of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the transaction, the director now directly owns 25,000 shares of the company's stock, valued at $500,500. This trade represents a 25.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 50.07% of the company's stock.
Institutional Trading of Phibro Animal Health
A number of hedge funds and other institutional investors have recently modified their holdings of PAHC. Sofinnova Investments Inc. purchased a new position in Phibro Animal Health during the second quarter worth about $3,975,000. American Century Companies Inc. lifted its holdings in shares of Phibro Animal Health by 119.6% in the 2nd quarter. American Century Companies Inc. now owns 347,191 shares of the company's stock worth $5,822,000 after acquiring an additional 189,068 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Phibro Animal Health by 116.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company's stock worth $4,330,000 after purchasing an additional 103,491 shares during the period. Dana Investment Advisors Inc. increased its holdings in Phibro Animal Health by 17.2% in the 2nd quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company's stock valued at $8,619,000 after purchasing an additional 75,546 shares during the last quarter. Finally, Algert Global LLC raised its position in Phibro Animal Health by 521.1% in the third quarter. Algert Global LLC now owns 71,335 shares of the company's stock valued at $1,606,000 after purchasing an additional 59,850 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.
About Phibro Animal Health
(
Get Free Report)
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Featured Stories
Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
